Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. [electronic resource]
Producer: 20170824Description: 779-791 p. digitalISSN:- 1474-5488
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Bevacizumab -- administration & dosage
- Carboplatin -- administration & dosage
- Carcinoma, Ovarian Epithelial
- Cytoreduction Surgical Procedures
- Disease-Free Survival
- Fallopian Tube Neoplasms -- therapy
- Female
- Humans
- Middle Aged
- Neoplasm Recurrence, Local -- therapy
- Neoplasms, Glandular and Epithelial -- therapy
- Ovarian Neoplasms -- therapy
- Paclitaxel -- administration & dosage
- Peritoneal Neoplasms -- therapy
- Survival Rate
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.